{"title":"帕罗西汀改善难治性慢性疼痛患者的疼痛和抑郁","authors":"A. Kanai, H. Okamoto","doi":"10.1179/016911107X396853","DOIUrl":null,"url":null,"abstract":"Abstract Objective: Patients with chronic pain frequently have depression, which may augment their pain. The selective serotonin re-uptake inhibitor, paroxetine, is widely used in the treatment of depression. The purpose of this study was to examine the effectiveness of paroxetine in the treatment of refractory chronic pain. Patients and methods: Fifty patients with a history of at least 6-month persistent chronic pain participated in this study. Paroxetine was orally administered once daily at a dose of 10 mg initially, then increased weekly by 10 mg until a maximum of 40 mg. The dose was reduced when an adverse reaction occurred, and treatment was continued for 2 weeks at the optimal dose. Depression was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). The state of depression was evaluated using the Self-Rating Depression Scale (SDS), and that of pain using the Visual Analogue Scale (VAS). Results: Overall, 70% of the patients had depression. The SDS score was h...","PeriodicalId":19808,"journal":{"name":"Pain Clinic","volume":"15 1","pages":"235-239"},"PeriodicalIF":0.0000,"publicationDate":"2007-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Paroxetine improves pain and depression in patients with refractory chronic pain\",\"authors\":\"A. Kanai, H. Okamoto\",\"doi\":\"10.1179/016911107X396853\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Objective: Patients with chronic pain frequently have depression, which may augment their pain. The selective serotonin re-uptake inhibitor, paroxetine, is widely used in the treatment of depression. The purpose of this study was to examine the effectiveness of paroxetine in the treatment of refractory chronic pain. Patients and methods: Fifty patients with a history of at least 6-month persistent chronic pain participated in this study. Paroxetine was orally administered once daily at a dose of 10 mg initially, then increased weekly by 10 mg until a maximum of 40 mg. The dose was reduced when an adverse reaction occurred, and treatment was continued for 2 weeks at the optimal dose. Depression was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). The state of depression was evaluated using the Self-Rating Depression Scale (SDS), and that of pain using the Visual Analogue Scale (VAS). Results: Overall, 70% of the patients had depression. The SDS score was h...\",\"PeriodicalId\":19808,\"journal\":{\"name\":\"Pain Clinic\",\"volume\":\"15 1\",\"pages\":\"235-239\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pain Clinic\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1179/016911107X396853\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain Clinic","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1179/016911107X396853","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Paroxetine improves pain and depression in patients with refractory chronic pain
Abstract Objective: Patients with chronic pain frequently have depression, which may augment their pain. The selective serotonin re-uptake inhibitor, paroxetine, is widely used in the treatment of depression. The purpose of this study was to examine the effectiveness of paroxetine in the treatment of refractory chronic pain. Patients and methods: Fifty patients with a history of at least 6-month persistent chronic pain participated in this study. Paroxetine was orally administered once daily at a dose of 10 mg initially, then increased weekly by 10 mg until a maximum of 40 mg. The dose was reduced when an adverse reaction occurred, and treatment was continued for 2 weeks at the optimal dose. Depression was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). The state of depression was evaluated using the Self-Rating Depression Scale (SDS), and that of pain using the Visual Analogue Scale (VAS). Results: Overall, 70% of the patients had depression. The SDS score was h...